Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Clare Braun Hashemi

Neurology Owensboro, KY Medical Doctor

NPI 1801908025 CMS profile 263152

1301 Pleasant Valley Rd, Suite 500C, Owensboro, KY 42303

Open in the dashboard

General payments

$4,015

217 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Clare Braun Hashemi of Owensboro, KY is reported in the CMS Open Payments database as having received $4,015 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $16 1
2023 General $93 4
2022 General $602 33
2021 General $945 54
2020 General $1,123 68
2019 General $1,236 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clare Braun Hashemi
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Clare Braun Hashemi were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Clare Braun Hashemi Neurology median Middle half National median
2019 $1,236 $474 $118–$2,177 $163
2020 $1,123 $367 $82–$2,309 $114
2021 $945 $438 $104–$2,547 $132
2022 $602 $442 $103–$2,388 $149
2023 $93 $464 $119–$2,312 $160
2024 $16 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Amgen Inc. $428 21 payments
  2. Avanir Pharmaceuticals, Inc. $335 19 payments
  3. AbbVie, Inc. $281 18 payments
  4. Biogen, Inc. $202 11 payments
  5. ACADIA Pharmaceuticals Inc $179 11 payments
  6. CSL Behring $174 10 payments
  7. EMD Serono, Inc. $166 10 payments
  8. Amneal Pharmaceuticals LLC $164 7 payments
  9. Genzyme Corporation $139 5 payments
  10. Novartis Pharmaceuticals Corporation $136 9 payments
  11. Other $1,811 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,900 211 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $114 6 payments
Products named General payments · program years 2019–2024
  1. AIMOVIG $473 24 payments
  2. NUEDEXTA $335 19 payments
  3. Hizentra $174 10 payments
  4. RYTARY $164 7 payments
  5. NUPLAZID $158 10 payments
  6. UBRELVY $149 11 payments
  7. BOTOX $139 9 payments
  8. Mavenclad $127 8 payments
  9. INBRIJA $114 6 payments
  10. APTIOM $108 7 payments
  11. Other $2,154 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record